Variable | RR | (95% CI) | pvalue |
---|---|---|---|
Age ≥ 50 years | 0.94 | (0.63, 1.40) | 0.760 |
ECOG performance status | Â | Â | Â |
   2 – 3 versus 0 – 1 | 1.81 | (1.21, 2.72) | 0.004 |
Hydroxyproline/Creatinine ratio (centered) | 1.00 | (0.97, 1.04) | 0.921 |
Bone-specific alkaline phosphatase, U/L | 1.01 | (1.00, 1.01) | 0.204 |
Estrogen-receptor status versus negative | Â | Â | Â |
   Positive | 0.56 | (0.34, 0.92) | 0.023 |
   Unknown | 0.89 | (0.58, 1.36) | 0.580 |
Progesterone-receptor status versus negative | Â | Â | Â |
   Positive | 0.62 | (0.38, 1.01) | 0.053 |
   Unknown | 0.78 | (0.52, 1.16) | 0.214 |
Sites of metastasis (yes versus no) | Â | Â | Â |
   Bone as only metastatic site | 0.84 | (0.57, 1.24) | 0.392 |
   Lung | 1.32 | (0.77, 2.29) | 0.317 |
   Liver | 1.26 | (0.75, 2.13) | 0.379 |
Time from diagnosis of bone metastases to study entry, years | 1.00 | (0.95, 1.04) | 0.912 |
Time from cancer diagnosis to study entry, years | 1.00 | (0.96, 1.04) | 0.947 |
Lesion characteristics and numbers | Â | Â | Â |
   ≥ 3 osteolytic versus < 3 osteolytic | 1.92 | (1.29, 2.84) | 0.001 |
   1 – 2 osteoblastic versus no osteoblastic | 1.28 | (0.82, 2.02) | 0.282 |
   ≥ 3 osteoblastic versus no osteoblastic | 0.39 | (0.32, 0.50) | < 0.001 |
   1 – 2 mixed versus no mixed | 1.16 | (0.64, 2.09) | 0.624 |
   ≥ 3 mixed versus no mixed | 1.26 | (0.77, 2.06) | 0.352 |
Prior fracture (yes versus no) | 1.78 | (1.12, 2.81) | 0.014 |
Pain scores (centered) | 1.29 | (1.19, 1.40) | < 0.001 |
Prior chemotherapy (yes versus no) | 0.89 | (0.32, 2.48) | 0.816 |
≥ 2 prior hormonal therapies (yes versus no) | 1.11 | (0.75, 1.63) | 0.605 |
Prior radiotherapy (yes versus no) | 2.02 | (1.35, 3.02) | < 0.001 |